CA125 is a kind of glycoprotein that can combine with monoclonal antibody OC125. 

It was derived from the embryonic development body cavity epithelium and did not exist in normal ovarian tissue. 

The most commonly detected in the serum of epithelial ovarian cancer patients who are diagnosed with severe tumors. Therefore, its diagnostic sensitivity is high and can use as one of the markers for the early diagnosis of ovarian epithelial carcinoma.

SEKBIO is now offering Mouse anti-human CA125 mAb, Humanized anti-human CA125 mAb on B-domain, and Mouse anti-human CA125 mAb on C-domain for detection usage, which can use on multiple platforms.

CA125 Products

Mouse anti-human CA125 mAb

For immunodiagnostic: ELISA, LFA, CLIA

Humanized anti-human CA125 mAb

CA125 Antigen

Cancer antigen 125 is the most commonly used tumor marker in gynecological tumors. Cancer antigen 125 is a glycoprotein tumor-associated antigen present in the epithelial cells of ovarian tumors. When suffering from epithelial ovarian cancer and endometrial cancer, the serum CA125 level of patients can be significantly increased.

CA125 Test

The level of serum CA125 in patients with ovarian cancer is significantly increased. Its positive rate can reach 97%, so it has significant clinical value in diagnosing ovarian cancer, especially for observing the treatment effect and judging recurrence. Other cancers, such as cervical cancer, breast cancer, pancreatic cancer, biliary tract cancer, liver cancer, stomach cancer, colorectal cancer, lung cancer, etc., also have specific positive reactions. In addition, 3% to 6% of patients with benign ovarian tumors and uterine fibroids sometimes increase serum CA125, but most of them do not exceed 100,000 u/L. Serum CA125 was significantly increased in decompensated cirrhosis.